Allo-SCT for hematological malignancies in the setting of HIV

@article{Polizzotto2010AlloSCTFH,
  title={Allo-SCT for hematological malignancies in the setting of HIV},
  author={Mark N. Polizzotto and Martha Skinner and Merrole F. Cole-Sinclair and Stephen S. Opat and Andrew Spencer and Susan Avery},
  journal={Bone Marrow Transplantation},
  year={2010},
  volume={45},
  pages={584-586}
}
The advent of highly active antiretroviral therapy (HAART) has transformed the clinical outcomes for people with HIV. Antiviral therapies deliver suppression of viral replication with immune reconstitution, an attendant decrease in opportunistic infections, and improvements in life expectancy. Nonetheless, the rates of intercurrent malignancies remain elevated, with hematological malignancies prominent. Optimal management of malignancies in patients with HIV remains incompletely defined… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2008

Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with malignant and non-malignant disorders

V Gupta, M Tomblyn, +3 authors J Storek
Biol Blood Marrow Transplant • 2007

HIV-Infected Liver and Kidney Transplant Recipients : 1-and 3-Year Outcomes

M. E. Rolanda, B. Barinb, +18 authors P. G. Stocka
2007

Similar Papers

Loading similar papers…